- Home
- CIO vs DMAC Comparison
CIO vs DMAC Comparison
Compare CIO & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIO
- DMAC
- Stock Information
- Founded
- CIO 2013
- DMAC 2000
- Country
- CIO Canada
- DMAC United States
- Employees
- CIO N/A
- DMAC N/A
- Industry
- CIO Real Estate Investment Trusts
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CIO Real Estate
- DMAC Health Care
- Exchange
- CIO Nasdaq
- DMAC Nasdaq
- Market Cap
- CIO 230.9M
- DMAC 228.3M
- IPO Year
- CIO 2014
- DMAC N/A
- Fundamental
- Price
- CIO $5.34
- DMAC $4.97
- Analyst Decision
- CIO
- DMAC Strong Buy
- Analyst Count
- CIO 0
- DMAC 3
- Target Price
- CIO N/A
- DMAC $7.00
- AVG Volume (30 Days)
- CIO 378.8K
- DMAC 155.8K
- Earning Date
- CIO 10-31-2024
- DMAC 11-13-2024
- Dividend Yield
- CIO 7.11%
- DMAC N/A
- EPS Growth
- CIO N/A
- DMAC N/A
- EPS
- CIO N/A
- DMAC N/A
- Revenue
- CIO $173,528,000.00
- DMAC N/A
- Revenue This Year
- CIO N/A
- DMAC N/A
- Revenue Next Year
- CIO $0.90
- DMAC N/A
- P/E Ratio
- CIO N/A
- DMAC N/A
- Revenue Growth
- CIO N/A
- DMAC N/A
- 52 Week Low
- CIO $4.02
- DMAC $2.14
- 52 Week High
- CIO $6.63
- DMAC $5.74
- Technical
- Relative Strength Index (RSI)
- CIO 54.19
- DMAC 53.46
- Support Level
- CIO $5.58
- DMAC $5.06
- Resistance Level
- CIO $5.87
- DMAC $5.74
- Average True Range (ATR)
- CIO 0.16
- DMAC 0.34
- MACD
- CIO 0.00
- DMAC -0.04
- Stochastic Oscillator
- CIO 46.84
- DMAC 25.79
About CIO City Office REIT Inc.
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. The company owns office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.